H-Index
70
Scimago Lab
powered by Scopus
Clarivate
Analytics
Formerly the IP & Science
business of Thomson Reuters

Logo




eISSN: 1643-3750

Targeting Smoothened Sensitizes Gastric Cancer to Chemotherapy in Experimental Models

Huifa Ma, Yongsheng Tian, Xiangyang Yu

(Department of General Surgery, Tianjin Hospital, Tianjin, China (mainland))

Med Sci Monit 2017; 23:1493-1500

DOI: 10.12659/MSM.903012

Published: 2017-03-28


BACKGROUND: The Hedgehog pathway receptor smoothened (SMO) has critical roles in tumor progression. However, whether SMO is a key factor regulating gastric cancer chemotherapy resistance is unknown.
MATERIAL AND METHODS: We investigated the potential functions of SMO in inducing gastric cancer paclitaxel resistance in clinical samples, gastric cancer cell lines (424GC and AGS), and subcutaneous syngeneic mouse models.
RESULTS: We found high SMO expression in paclitaxel-resistant gastric cancer clinical samples. Paclitaxel gastric cancer cells had higher SMO expression than in drug-sensitive cells. Upregulating SMO expression induced paclitaxel resistance in gastric cells lines via enhancing cell proliferation and inhibiting apoptosis. The combination of IPI-926, an inhibitor of SMO, with paclitaxel decreased cell viability of paclitaxel-resistant gastric cancer cells in vitro and controlled tumor growth in animal models.
CONCLUSIONS: The Hedgehog pathway receptor SMO is an important regulator of gastric cancer paclitaxel resistance and could be a target for sensitizing paclitaxel-resistant tumors.

Keywords: Antineoplastic Agents, Drug Resistance, Hedgehog Proteins, Stomach Neoplasms



Back